Founded in 2022 and based in Berlin, Germany, Silica Corpora develops a De Novo AI platform to design and optimize therapeutic antibodies. Our mission is to accelerate antibody discovery and reduce the time and cost of preclinical development by producing high-quality antibody candidates from amino acid sequence data.

We use proprietary AI and machine-learning modules (Generator, Discriminator, Optimizer, and Ep-Mapper) that operate on amino acid sequences to generate, evaluate, and adapt antibody candidates. The platform predicts developability, stability, solubility, aggregation, and immunogenicity, and can be tuned to project-specific target product profiles while integrating with existing in vitro workflows.

Silica Corpora partners with academic and industry organizations to apply its platform to priority disease programs and extract additional value from historical and project data.